☆ 4.3 Article

Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas

CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Pharmacology & Pharmacy

Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients

Matteo Megna et al.

Summary: This article reviews the current literature on the use of biologic drugs and oral small molecules (OSM) for the treatment of pediatric psoriasis and concludes that they are an ideal treatment option with excellent efficacy and safety profiles compared to traditional systemic drugs.

EXPERT OPINION ON DRUG SAFETY (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients

Matteo Megna et al.

Summary: The management of moderate-to-severe forms of psoriasis in elderly patients is a frequent concern due to the higher risk of adverse events, logistic issues, and comorbidities. Traditional systemic treatments are often contraindicated, making biologic drugs and small molecules a valuable option. However, data on their effectiveness and safety in elderly patients are limited.

EXPERT OPINION ON DRUG SAFETY (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation

Angelo Ruggiero et al.

Summary: Biological treatments have revolutionized the management of moderate-to-severe psoriasis, and bimekizumab, a novel IL-17 inhibitor, shows unique efficacy and safety profiles compared to other biologics. This review evaluates the safety of bimekizumab in treating moderate-to-severe plaque psoriasis and highlights its superior efficacy compared to other biological classes.

EXPERT OPINION ON DRUG SAFETY (2023)

添加到收藏夹

Article Medicine, General & Internal

Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study

Matteo Megna et al.

Summary: This study investigated the long-term efficacy and safety of risankizumab for the management of moderate to severe psoriasis. The results showed significant reduction in psoriasis severity scores from week 16 and maintained up to week 104, with no serious adverse events reported.

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

Article Dermatology

Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials

Boni Elewski et al.

Summary: The efficacy of brodalumab in treating nail or scalp psoriasis was evaluated in three phase 3 studies. The results showed that brodalumab led to scalp clearance within 12 weeks and improvements in nail psoriasis within 52 weeks.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Review Dermatology

Soluble biomarkers for diagnosis, monitoring, and therapeutic response assessment in psoriasis

Mohammad Reza Pourani et al.

Summary: This review evaluated potential biomarkers for the diagnosis of psoriasis, its associated comorbidities, and response to treatment, including risk prediction, disease activity, psoriatic arthritis, and monitoring therapy. While a wide range of markers have been investigated, most are not used in routine clinical practice, highlighting the importance of thorough physical examinations and clinical scoring systems like the Psoriasis Area and Severity Index score.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Article Dermatology

Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and-3

K. Reich et al.

Summary: Treatment with brodalumab resulted in sustained high levels of skin clearance in patients with moderate-to-severe psoriasis, with a high proportion of patients achieving PASI 90 at Week 120. The treatment was well tolerated and had a similar safety profile to previous studies, supporting its long-term efficacy and safety.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

添加到收藏夹

Article Dermatology

Comparison of dermoscopy and reflectance confocal microscopy accuracy for the diagnosis of psoriasis and lichen planus

Zi-Yi Wang et al.

Summary: This study aimed to compare the diagnostic accuracy of dermoscopy and reflectance confocal microscopy (RCM) in inflammatory skin diseases. The results showed that dermoscopy was more accurate in diagnosing psoriasis, while RCM had higher accuracy in diagnosing lichen planus.

SKIN RESEARCH AND TECHNOLOGY (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge

Angelo Ruggiero et al.

Summary: Our analysis showed tildrakizumab as a generally safe option for the treatment of psoriasis, with most of the reported adverse events being classified as mild or moderate, and rarely requiring treatment discontinuation.

EXPERT OPINION ON DRUG SAFETY (2022)

添加到收藏夹

Article Dermatology

Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting

Matteo Megna et al.

Summary: This study compared the efficacy and safety of Ixekizumab and Brodalumab in patients with psoriasis, and found that they were comparable in terms of effectiveness and safety.

DERMATOLOGIC THERAPY (2022)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Treating psoriasis in the elderly: biologics and small molecules

Matteo Megna et al.

Summary: Psoriasis prevalence in the elderly is increasing, requiring systemic treatments. However, conventional systemic agents have limitations, while biologics and small molecules are valuable options. Although elderly psoriasis patients are often excluded from trials and guidelines are lacking, real-world data support the efficacy and safety of biologics and small molecules in this population.

EXPERT OPINION ON BIOLOGICAL THERAPY (2022)

添加到收藏夹

Editorial Material Biotechnology & Applied Microbiology

New frontiers in personalized medicine in psoriasis

Elisa Camela et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2022)

添加到收藏夹

Review Biology

Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness

Alin Codrut Nicolescu et al.

Summary: The severity evaluation of psoriasis in difficult-to-treat areas is a major challenge. There is controversy surrounding whether these areas should be evaluated differently. This review proposes solutions such as using special scores or adding correction factors to assess the severity of these areas within the existing scores.

LIFE-BASEL (2022)

添加到收藏夹

Review Dermatology

Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis

Alan Menter et al.

Summary: Psoriatic involvement in specific areas such as nails, palms and soles, and scalp has a significant negative impact on quality of life. Although there is evidence for the efficacy of biologics in overall skin clearance for moderate-to-severe plaque psoriasis, more large-scale, randomized, placebo-controlled clinical studies are needed for psoriasis with nail, palmoplantar, and scalp involvement. Additionally, biologic failure due to drug ineffectiveness is common in patients who do not respond well to treatment or become intolerant. Brodalumab, a fully human IL-17 receptor A antagonist, has shown high rates of skin clearance in difficult-to-treat psoriasis.

DERMATOLOGY AND THERAPY (2022)

添加到收藏夹

Letter Dermatology

Tildrakizumab for the treatment of moderate to severe psoriasis: Results from a single center preliminary real-life study

Angelo Ruggiero et al.

DERMATOLOGIC THERAPY (2022)

添加到收藏夹

Letter Dermatology

Brodalumab efficacy in bio-naive psoriasis patients: real-life experience of 202 subjects up to 48 weeks

Luca Mastorino et al.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Article Dermatology

Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry

Kristina Callis Duffin et al.

Summary: This study characterized patients with psoriasis in challenging-to-treat areas in routine US clinical practice, finding that these patients had worse patient-reported outcomes compared to those without challenging-to-treat localizations. The findings suggest a significant burden of challenging-to-treat areas on patients' quality of life.

DERMATOLOGY (2021)

添加到收藏夹

Article Dermatology

Dermoscopy of plaque psoriasis differs with plaque location, its duration, and patient's sex

Joanna Golinska et al.

Summary: The dermoscopic features of psoriatic plaques may vary with anatomical location, duration of the lesion, and the patient's sex.

SKIN RESEARCH AND TECHNOLOGY (2021)

添加到收藏夹

Article Dermatology

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations

A. Nast et al.

Summary: This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clinical and comorbid situations such as treating psoriasis vulgaris patient with concomitant psoriatic arthritis, concomitant inflammatory bowel disease.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?

Matteo Megna et al.

Summary: The study aimed to evaluate the prevalence of paradoxical PsA in psoriasis patients under biologic therapy, and found that 10 out of 118 patients developed new-onset PsA, with no significant risk factors identified.

BIOMEDICINES (2021)

添加到收藏夹

Letter Dermatology

Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?

Matteo Megna et al.

DERMATOLOGIC THERAPY (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy

M. Galluzzo et al.

Summary: Real-life study on 90 patients with moderate-to-severe psoriasis treated with brodalumab showed that after 48 weeks, 92.2% of patients achieved a PASI score of <3. This suggests that brodalumab is effective and safe in treating patients with moderate-to-severe chronic psoriasis in a real-world setting.

EXPERT OPINION ON BIOLOGICAL THERAPY (2021)

添加到收藏夹

Review Dermatology

Management of psoriasis as a systemic disease: what is the evidence?

N. J. Korman

BRITISH JOURNAL OF DERMATOLOGY (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

The safety of brodalumab for the treatment of psoriasis

Helena Iznardo et al.

EXPERT OPINION ON DRUG SAFETY (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review

Masahiro Kamata et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

添加到收藏夹

Review Medicine, General & Internal

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review

April W. Armstrong et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

New Treatment Addressing the Pathogenesis of Psoriasis

Michio Tokuyama et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

添加到收藏夹

Article Dermatology

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations

A. Nast et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)

添加到收藏夹

Article Dermatology

Localization of treatment-resistant areas in patients with psoriasis on biologics

K. F. Hjuler et al.

BRITISH JOURNAL OF DERMATOLOGY (2019)

添加到收藏夹

Review Dermatology

Psoriasis and the TNF/IL23/IL17 axis

Kazuhisa Furue et al.

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA (2019)

添加到收藏夹

Review Dermatology

Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails

Joseph F. Merola et al.

DERMATOLOGIC THERAPY (2018)

添加到收藏夹

Review Pharmacology & Pharmacy

Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas

Dario Kivelevitch et al.

EXPERT OPINION ON PHARMACOTHERAPY (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

Protein biomarker for psoriasis: A systematic review on their role in the epathomechanism, diagnosis, potential targets and treatment of psoriasis

Krishna Yadav et al.

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2018)

添加到收藏夹

Review Allergy

The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis

Andrew Blauvelt et al.

CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2018)

添加到收藏夹

Review Pharmacology & Pharmacy

Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis

N. Malecic et al.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)

添加到收藏夹

Article Dermatology

Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study

Hidemi Nakagawa et al.

JOURNAL OF DERMATOLOGICAL SCIENCE (2016)

添加到收藏夹

Review Dermatology

Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials

Benjamin Farahnik et al.

DERMATOLOGY AND THERAPY (2016)

添加到收藏夹

Review Dermatology

Dermoscopy in General Dermatology: A Practical Overview

Enzo Errichetti et al.

DERMATOLOGY AND THERAPY (2016)

添加到收藏夹

Article Dermatology

Psoriasis: classical and emerging comorbidities

Maria de Fatima Santos Paim de Oliveira et al.

ANAIS BRASILEIROS DE DERMATOLOGIA (2015)

添加到收藏夹

Article Medicine, General & Internal

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

M. Lebwohl et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Review Dermatology

C- reactive protein in psoriasis: a review of the literature

S. Beygi et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)

添加到收藏夹

Article Dermatology

Accuracy of dermoscopic criteria for the diagnosis of psoriasis, dermatitis, lichen planus and pityriasis rosea

A. Lallas et al.

BRITISH JOURNAL OF DERMATOLOGY (2012)

添加到收藏夹

Article Medicine, General & Internal

Psoriasis 1 - Pathogenesis and clinical features of psoriasis

Christopher E. M. Griffiths et al.

LANCET (2007)

添加到收藏夹

Article Rheumatology

Psoriasis: epidemiology, clinical features, and quality of life

RGB Langley et al.

ANNALS OF THE RHEUMATIC DISEASES (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.